Tag: NonMain

Takeda Completes Sale of Decide on Non-Main Property to Cheplapharm

OSAKA, Japan–(Business WIRE)–Takeda Pharmaceutical Corporation Restricted (TSE:4502/NYSE:TAK) (“Takeda”) right now declared the completion of its beforehand-introduced sale of a portfolio of select prescription solutions to Cheplapharm for a full worth of $562 million USD1. The portfolio features 16 prescription pharmaceutical items bought predominantly in Europe which is section of Takeda’s Europe and Canada Business enterprise Unit. This divestment agreement was… Read more →